Mexican Consensus on the Management of Bone Metastases in Prostate Cancer

MA Jiménez Ríos; J Moreno Aranda; FJ Ochoa Carrillo JS Aguilar Nieto; P Alfaro Ramírez; MA Aragón Castro; AR Aragón Tovar; I Barragán Arteaga; E Barrera Juárez; F Calderón Ferro; S Carrillo Treviño; R Carvajal García; LM Covarrubias Rendón; SC de León Jaén; A de Silva Gutiérrez; A Farías Murguía; A Flores Guerrero; R Grimaldo Salazar; N Hernández Toriz; E Jamaica Verduzco; MA Erguera Rivera; L Lamm Wiechers; M Marquina Sánchez; C Martínez Arroyo; PF Martínez Cervera; A Medina Ocampo; A Mendoza Valdez; JA Narváez Morales; PA Patrón Sansor; A Torres García; A Robert Uribe; G Rodríguez Carrizosa; JA Rodríguez Rivera; A Rosas Ramírez; Solano Moreno; Yáñez Aguilar

2005, Number 1

Rev Mex Urol 2005; 65 (1)

Mexican Consensus on the Management of Bone Metastases in Prostate Cancer

Jiménez RMA, Moreno AJ, Ochoa CFJ, Aguilar NJS, Alfaro RP, Aragón CMA, Aragón TAR, Barragán AI, Barrera JE, Calderón FF, Carrillo TS, Carvajal GR, Covarrubias RLM, de León JSC, de Silva GA, Farías MA, Flores GA, Grimaldo SR, Hernández TN, Jamaica VE, Erguera RMA, Lamm WL, Marquina SM, Martínez AC, Martínez CPF, Medina OA, Mendoza VA, Narváez MJA, Patrón SPA, Torres GA, Robert UA, Rodríguez CG, Rodríguez RJA, Rosas RA, Solano M, Yáñez A

Full text

How to cite this article

Language: Spanish
References: 22
Page: 7-24
PDF size: 127.14 Kb.

ABSTRACT

With the aim of fulfilling the lack of knowledge of the clinical management of the bone disease related with prostate cancer among the health professionals in this country, a group of thirty six Mexican specialists in urology, oncology and surgery gathered between august 6th and October 16th in order to carry on the necessary efforts to establish the “First Mexican Consensus on the Management of Bone Metastases in Prostate Cancer”. The reunions took place in Mexico City (Group A: August 6th, Group B: August 7th, and Plenary Session: October 15th and 16th), in Guadalajara, Jalisco (August 21st), in Monterrey, Nuevo Leon (August 28th), in Merida, Yucatan (September 3rd) and Leon, Guanajuato (September 18th). At each of the meetings a base document was reviewed, presenting eventually the correspondent comments, changes and corrections, until this “consensus document” was achieved. In this document are highlighted the discussed criteria, concepts and guidelines, which are a useful guide for the management of this complex clinical condition which deeply compromises the prostate cancer patient’s quality of life. As we know, the bone complications related to malignancy impact in several ways the prostate cancer patients, promoting a significant fee of pain and disability due to pathological fractures & other complications that translate in the long run in greater economical costs due to disability, analgesic management, radio-therapy and surgery. Nowadays there is a relatively new family of drugs, known as bisphosphonates, that has consistently shown the capacity to avoid in a significant way the development of these complications, improving both the quality of life and the clinical prognostic of prostate cancer patients that usually spread through the so called bone metastases.

REFERENCES

Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002; 1(3): 145-52.
Lipton A, Small E, et al. The new bisphosphonate, zometa, (zoledronic acid), decreases skeletal complications. In both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20(Suppl. 2): 45-54.
Oefelein MG, Ricchiuti V, et al. Skeletal fractures negative correlate with overall survival in men with prostate cancer. J Urol 2002; 168(3): 1005-7.
Smith MR, Eastham J, Gleasom DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-12.
Saad F, Gleason D, Murray R, Venmner P, et al. Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone 2003 AUA Abstract # 2.
Lee R. Harland SJ, Oosterlinck. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
Saad F, Gleason D. El ácido zoledrónico reduce significativamente las fracturas en pacientes con CP con metástasis ósea, refractaria a hormonas. Annual Meeting of the American Urology Association Orlando FL, Mayo 25, 2002, Abstract 703.
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate cancer. J National Cancer Institute 2002; 94(19).
Dumond JC, Journé F, et al. Los bisfosfonatos inducen apoptosis in vitro en células de cáncer de próstata. ESMO, Octubre 18-22 del 2002, Niza/Francia.
10.Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmdyian S. Zoledronic acid increases bone mineral density men receiving androgen deprivation therapy for non-metastatic prostate cancer.
11.Hortobagyi GN, Theriault RL, Portes L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. Protocol 19 Aredia Brest Cancer Study Group. N Engl J Med 1996; 335: 1785-91.
12.Saad F, Gleason DM, Murray R, et al. A randomised, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68.
13.Thurman SA, Ramakrishna NR, De Weese TL. Radiation therapy for the treatment of locally advanced and metastatic prostatic cancer. Hematol Oncol Clin North Am 2001; 15: 423-43.
14.Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patient with painful bone metastases of prostate cancer. Eur J Nucl Med 2001; 28: 788-98.
Dickie GJ, Macfarlane D. Strontium and samarium therapy for bone metastases from prostate carcinoma. Australia Radiol 1999; 43: 476-9.
16.Turner SL, Gruenewald S, Spry N, Gebski V. Less pain does equal better quality of life following strontium 89 therapy for metastatic protate cancer. Br J Cancer 2001; 84: 297-302.
17.Brundage MD, Crook JM, Lukka H. Use of strontium 89 in endocrine refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group. Cancer Prev Control 1998; 2: 79-87.
18.Windsor PM. Predictors of response to strontium 89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre’s 10 year experience. Clin Oncol (R Coll Radiol) 2001; 13: 219-27.
19.Zyskowski A, Lamb D, Morum P, Hamilton D, Johnson C. Strontium 89 treatment for prostate cancer bone metastases: does a prostate specific antigen response predict for improved survival? Australas Radiol 2001; 45: 39-42.
20.Kraeber-Bodere F, Campion I, Rousseau C, Brourdin S, Chatal JF, Resche I. Treatment of bone metastases of prostate cancer with strontium 89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 2000; 27: 1487-93.
21.Akerley W, Butera J, Wehbe T, et al. A multiinstitutional, concurrent chemoradiation trial of strontium 89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 2002; 94: 1654-60.
22.Malmberg I, Persson U, Ask A, Tennvall J, Abrahmsson PA. Painful bone metastases in hormone refractory prostate cancer: economic cost of strontium 89 and/or external radiotherapy. Urology 1997; 50: 747-53.